Tuesday, May 25, 2021


Following are the oral comments presented to CHAC on behalf of the Beyond AIDS Foundation, on April 20, 2021.  CHAC is the official advisory committee to the Centers for Disease Control and Prevention (CDC), and the Health Resources and Services Administration (HRSA) concerning HIV, viral hepatitis, and sexually transmitted infections. A longer written document was also submitted.


I am Ronald Hattis, Secretary and Past-President of the Beyond AIDS Foundation. This is a brief synopsis of our written testimony, which I hope committee members will read for the rationale and details of our recommendations. For over 3 decades we have promoted improved strategies for HIV prevention and control. Among our leaders are former major metropolitan STD and HIV directors, health officers, EIS Officers, PACHA members, and HIV and other I.D. specialists. We hope to renew ongoing direct dialog with both agencies, and hope for inclusion in future CDC consultations. 

 Our recommendations are based in part on findings of our survey of state and territorial HIV/AIDS Directors, published in 2019 in AIDS Education and Prevention (and provided to the committee). This revealed marked inconsistencies of policy and practices among jurisdictions. Our most important recommendations for CDC and HRSA, include: 

  • That more oversight be provided and accountability required by both agencies regarding adherence to grant conditions. We recommend enhanced routine site visits for evaluation, education and guidance.  
  • That CDC recommendations, and grant requirements, specify more standardized public health outreach to newly diagnosed patients and their providers, particularly for rapid linkage to care and partner services. 20% of states and territories did not routinely contact all diagnosed patients and 40% did not try to contact all known providers. 

  • That CDC recommend, and include as a grant requirement, the monitoring of MISSED viral load results, none received in the past year for diagnosed patients, suggesting no active treatment. 

  • That monitoring of genotype results become a CDC recommendation, with results forwarded to CDC for analysis. Only 38% of jurisdictions even received such results. 

  • That all jurisdictions be encouraged to supplement CDC grants with their own money for HIV prevention. 28% of jurisdictions had no prevention funds other than their CDC grants.  That there be more joint screening efforts for HIV, STIs, and viral hepatitis, and more joint health education about their shared prevention measures, and that PrEP providers urge condom use to prevent other STIs.
  • That HRSA grant recipients, be expected to attempt to contact patients to remind them of upcoming appointments, to follow up on missed appointments, and when possible, 2 to schedule HIV care on the same half day as primary and specialty care. Providers funded through other sources should be encouraged to act similarly.
  • That PrEP costs be covered for uninsured patients, especially seronegative partners of Ryan White patients. HRSA efforts in this direction are appreciated.
  • Finally, that training be made available nationwide to primary care providers on starting immediate HIV treatment. Presentations that I have used to provide such training are linked from our written testimony. 

I am honored to have had this opportunity to provide input today. I welcome any questions, now or after this meeting

Tuesday, March 23, 2021


Ronald A. Hattis

Ronald P. Hattis, MD, MPH, Secretary and Past-President

There are mixed effects from communicating virtually (Zoom, Gotomeeting, etc.) and by email, rather than in person, with national and state public health leaders. On the one hand, it has saved us money that we would have needed to spend for travel to Washington, Sacramento, and New York, etc. On the other hand, not meeting in person makes it more difficult to establish the interpersonal connections that can be very helpful to sway thinking and influence public policy. 

In the last few months, our Beyond AIDS Foundation (BAF) has remotely submitted input for the 2021-2025 National HIV/AIDS Strategy, which was not incorporated into the final plan, but which we are still promoting as activities to optimally implement it.  I also provided public comment on March 9, 2021 on behalf or BAF to the Presidential Advisory Council on HIV/AIDS (PACHA), which reintroduced our organization to PACHA (on which two of our Board members had previously served), but did not result in any immediate action.  For both of these initiatives, we made reference to the findings and recommendations of our published survey of state and territorial HIV/AIDS Directors, in which we had found much inconsistency and some missed opportunities to enhance the HIV Care Continuum (HCC).

The HCC refers to the various stages that patients have to move through before the HIV virus can be suppressed to undetectable levels, resulting in almost no sexual transmission. Those stages include screening to diagnose infected persons, linking infected (HIV positive) persons to care, initiating antiviral treatment immediately or as soon as possible, retaining treated patients in care, and suppressing the "viral load." There is dropout at each stage, and a major pubic health objective is to reduce the dropout rates so that the vast majority of patients can reach the ultimate goal of viral suppression, and consequently not passing the virus on to others. The concept is sometimes called "treatment as prevention," something to which I have a strong personal commitment, as one of the first people to advocate it, back in 1996. It was eventually adopted as a cornerstone of US HIV strategy, but not until 15 years later.

Beyond AIDS Foundation specifically advocates that state and local public health staff reach out to patients and providers as soon as a new positive HIV test is reported, to urge and help arrange linkage to a source of HIV care, to perform or arrange for partner services (contact tracing and partner notification). and to discuss other relevant concerns. In our survey, we found that most jurisdictions did this, but that some were not doing so routinely.  We also advocate that public health departments keep track of a specific reportable HIV test, the viral load, which measures virus in the blood. If test results show high levels of virus that are not dropping, we suggest that providers be contacted to see whether anything can be done to assist. If no viral load tests are reported for a year, there should also be outreach to find out whether the patient has dropped out of care or moved to another jurisdiction, either of which deserves follow-up. Over 40% of jurisdictions had on their own initiative started looking for such "missed viral load results" in diagnosed persons, even though CDC had not required this. We think that this practice should become universal and an expectation of CDC. When medical appointments for HIV patients are missed, providers should be expected to reach out to patients to persuade them to make new appointments, and if are no longer reachable, public health should be notified.

 We also recommend that all states and territories make genotype results, which indicate whether the virus is sensitive or resistant to various medications, reportable to public health.  In our survey, in 62% of jurisdictions these were not reportable. We also recommend that genotype results, or aggregate summaries, be forwarded to CDC so that there can be full national surveillance for the emergency of resistant strains. We also found that 28% of states and territories were relying entirely on CDC grants for HIV prevention. CDC money will often be the biggest source of funding for HIV prevention, but is usually not sufficient by itself, and should be supplemented by additional funding raised by states, local jurisdictions, and/or private sources.

Upcoming is another opportunity for our Foundation to capture the attention of some key federal public health leaders. We plan a brief BAF presentation during the public comment period at the April 20, 2021 meeting of CHAC, an advisory committee to CDC (Centers for Disease Control and Prevention) and HRSA (Health Resources and Services Administration) regarding HIV, STDs, and viral hepatitis programs. This may be our most important interaction with federal personnel, because most of the recommendations of our survey article were for CDC and to a lesser extent HRSA to consider some changes to what is expected in return for their grants.

Internally, this year we will be updating our Foundation's objectives and declarations, which are over a decade old. We will also be looking for opportunities for involvement "beyond AIDS." As the pandemic diverts staff from control of sexually transmitted infections, rates of some of those infections have risen, and there is a risk that HIV infections may as well. Ongoing prevention and control efforts for all these diseases should not suffer as the pandemic progresses into its second year.

Saturday, December 12, 2020



Ronald P. Hattis, MD, MPH

Prepared for Beyond AIDS Foundation as a resource to providers, updated 5/20/21

In 1987, AZT (now rarely used), a nucleoside reverse transriptase inhibitor (NRTI) originally studied as a possible anti-cancer remedy, became the first antiviral drug approved for AIDS by the FDA. Monotherapy helped temporarily, but typically resulted in the development of viral resistance. As more NRTIs were developed and over the next few years, combinations of two of them were found to be more effective than monotherapy, but still not adequate as a total regimen for treatment because of some eventual resistance and progression of disease. (Later, however, some duo combinations were found to be useful for pre-exposure prophylaxis or PrEP, see below).

Starting in 1996 (when protease inhibitors became available) and until very recently, the standard of care for “highly effective anti-retroviral therapy” (HAART) for HIV has been a combination of three drugs in one or more pills. These have included 2 NRTIs, or in the most highly recommended combinations of recent years, one NRTI plus the highly effective and chemically similar nucleotide reverse transcriptase inhibitor tenofovir disoproxil, approved in 2001.  An alternative form of tenofovir, alefenamide instead of disoproxil, was approved 15 years later and is discussed below. The term N(t)RTI is now sometimes used to refer jointly to the nucleosides and nucleotides.  Regimens that include N(t)RTIs all utilize either emtracitabine or the similar (and generically available) lamivudine, as these are considered to be the least toxic in the group. Those regimens that still include 2 N(t)RTIs combine one of these with either of those two forms of tenofovir, or with a less commonly used alternative, abacavir.

The third drug is selected from a separate class of antivirals. There are now several antiviral drug classes effective against HIV, but based on effectiveness and safety, one has become the class of choice to give with 2 N(t)RTIs as a complete regimen for treating HIV (and especially for starting treatment), This preferred class is the integrase strand transfer inhibitors, known for short as integrase inhibitors or INSTIs. Recently developed INSTIs (dolutegravir, bictegravir, and cabotegravir) have shown great effectiveness and negligible viral resistance, raising the prospect that they might be effective with only one other drug for treatment. This has already been approved for dolutegravir plus one NRTI, lamivudine. Cabotegravir has been approved in a long activing injection with one other drug, and has been proposed for use alone for PrEP, see below. This has influenced three of the new developments below. Unfortunately, INSTI drugs, and particularly dolutegravir and bictegravir, have been associated with weight gain.

Two drugs, ritonavir and cobicistat, are used solely as "boosters" to raise the level of another drug. All of the protease inhibitors are now given with a "booster," as is one of the INSTIs, elvitegravir.

In 2001, tenofovir disoproxil plus an NRTI, emtracitabine, were approved as the first drug combination (Truvada) for pre-exposure prophylaxis (PrEP). Unfortunately, tenofovir disoproxil has some mild toxicity to bone and kidney, which is a concern in particular when treating persons who are well and not infected. Fortunately, a pro-drug alternative lacking those bone and kidney side effects, tenofovir alefenamide, has been developed by the same company, and has been implemented both for treatment and for PrEP. That is one of the new developments discussed below. However, a countervailing consideration is that tenofovir disoproxil actually has some beneficial effects on lipids, which are reversed by switching to the alefenamide preparation. Also, tenofovir alefenamide has been associated with more weight gain than the disoproxil. So treatment choices should be individualized in patients with hyperlipidemia or obesity, and strong bones and kidneys.

  1. Dovato (dolutegravir with lamivudine), was approved 4//8/19 as the first 2-drug combination sufficient for a complete treatment regimen. HHS treatment guidelines suggest that this be an approved starting regimen, except for patients with pre-treatment HIV RNA >500,000 copies/mL, or who are known to have active hepatitis B virus (HBV) coinfection; or who will initiate ART before results of HIV genotype testing for reverse transcriptase or HBV testing are available  (https://www.fda.gov/news-events/press-announcements/fda-approves-first-two-drug-complete-regimen-hiv-infected-patients-who-have-never-received; https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf)

  1. Descovy (tenofovir alefenamide, the pro-drug of tenofovir not considered to be toxic to bone and kidneys but see above re lipids and weight gain, plus emtracitabine) was approved in 4/16 as part of treatment regimens, and 10/19 as the second combination for PrEP, a safer alternative to Truvada. Unfortunately, it has not been studied or approved for cis females exposed to sex by males. (https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic
  1. Cabotegravir is a new integrase transfer strand inhibitor, given by injection. When combined with a long-activing injectable form of rilpivirine (a member of the non-nuclease reverse transcriptase inhibitors, one of the other drug classes, and previously approved for daily oral use), it has proven effective. This combination was approved by FDA as Cabenuva on January 21, 2021, as a complete 2-drug treatment regimen.  It is administered monthly, with the starting dose 50% higher than subsequent doses. Meanwhile, cabotegravir alone is being studied and is expected to be approved as the first single-drug and first injectable PrEP.  In a small study with females in sub-Saharan Africa, it was more effective than Truvada as PrEP. Cabotegravir for this use was given a "breakthrough therapy designation" by FDA in November 2020, meaning that the agency will collaborate closely with the manufacturer in hopes of reaching approval in the near future.  (https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women; https://jamanetwork.com/journals/jama/article-abstract/2771873

In addition, two entirely new types of drugs discussed below have recently been developed for patients with strains of HIV highly resistant to usual medications.

  1. Trogarzo (ibalizumab-uiyk) is a new type of HIV drug for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV). It was approved by the FDA on 3/6/18. It must be administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications. It is the first CD4-directed post-attachment HIV-1 inhibitor, and binds to CD4+ receptors on host cells, blocking the HIV virus from infecting the cells. Additional drugs requiring IV infusion are in the pipeline. (https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-who-have-limited-treatment-options; https://www.prnewswire.com/news-releases/theratechnologies-announces-fda-approval-of-breakthrough-therapy-trogarzo-ibalizumab-uiyk-injection-the-first-hiv-1-inhibitor-and-long-acting-monoclonal-antibody-for-multidrug-resistant-hiv-1-300609280.html)
  1. Rukobia (Fostemsavir) is a new fusion/entry inhibitor for treatment-experienced adults with failing HIV-1 therapy. It was approved by the FDA on 7/2/20, and is taken orally twice a day.  (https://www.usnews.com/news/health-news/articles/2020-07-07/rukobia-approved-for-patients-with-multidrug-resistant-hiv)

As of 2021, there is a robust pipeline of new drugs in development, some of which are in clinical trials. Both oral and injectable new medications will tend to have long half-lives and not require daily dosage.

Sunday, August 04, 2019

Ronald P. Hattis, MD, MPH; Richel Y. Strydom, MD, MPH; Josileide Gaio, MPH; Deanna C. Stover, PhD, RN, FNP, CNS, COHN-S

Published February 2019, AIDS Education and Prevention, Volume 31, No. 1 https://doi.org/10.1521/aeap.2019.31.1.82

Corresponding author: Ronald P. Hattis, MD, MPH, Beyond AIDS Foundation, 404 New York St. #7718, Redlands, CA 92373, 909-838-4157, email: ronhattis@beyondaids.org.

Abstract and Conclusions provided here, including recommendations for CDC and HRSA:

We surveyed U.S. HIV/AIDS Directors or designees in states and non-state regions, regarding factors influencing HIV viral suppression: 1) non-federal prevention funding; 2) contacting newly-reported patients and providers, for care linkage and partner services; 3) follow-up of non-received viral load reports, to identify untreated patients; and 4) genotype/phenotype surveillance, to monitor drug resistance. The survey was conducted April-July 2015; 50 (87.7%) participated.  Of jurisdictions, 80% contacted all newly-reported patients; 60% contacted all providers. HIV resistance tests were reportable in 38%; 66% contacted providers and/or patients about missed viral loads. Non-federal funding was significantly associated with annual diagnoses (p=0.0001) and population (p=0.0002), but not with other factors studied. Many jurisdictions lacked non-federal funding (28%), or experienced unrestored reductions since 2008 (33%).  Jurisdictions’ funding and preventive practices varied greatly.  HIV viral suppression could be enhanced by restoring (or establishing) non-federal prevention funding, and by more standardized surveillance/outreach practices.


After several years of economic recovery, restoration of recession funding cutbacks for HIV prevention was overdue at jurisdictional and local levels. Federal matching of non-federal funds could incentivize this. Restored (or newly established) non-federal funding could help monitor and facilitate progression through the HCC, especially if used in part for outreach to patients and their providers after new diagnoses or if viral load results were not received for a year, and for collection and forwarding of viral resistance data to CDC. However, such services, which were not yet specifically funded routinely by CDC, showed no statistical association with non-federal funding,.

Public health practices relating to follow-up of newly reported HIV diagnoses and missed viral load results, and reporting of genotypes and phenotypes, varied widely among states and NSRs. CDC could revise guidelines to encourage a more uniform system of HIV surveillance and monitoring, based on HCC stages and goals.

Linkage to care and partner services were already endorsed by CDC, but inconsistently applied. They could become a required use of CDC prevention funding, with specifications regarding the types of outreach expected.

Public health tracking of non-received viral load results (an indicator of infected persons who may not be in treatment), with outreach to providers and patients, may facilitate two more stages of the HCC: retention in care and antiretroviral treatment. Despite lack of specific funding by CDC, a majority of jurisdictions already claimed engagement in this activity.  Patient progression through the HCC could be facilitated by making it a required use for CDC and/or HRSA funding. To make this a universal surveillance activity, jurisdictions that do not have mandatory laboratory reporting of all viral loads, regardless of result, would need to institute such reporting.

CDC considered genotype surveillance optional, did not collect phenotypes, and neither was reportable in most jurisdictions. Uniform reporting, with submission to CDC for nationwide analysis, could produce a more complete database for monitoring antiretroviral resistance.

CDC could require grant application objectives to address jurisdiction-specific shortfalls in these areas, and opportunities for improvement.

Surveys like this may prove valuable in increasing awareness among public health advocates about funding gaps and potentials for expanded surveillance and outreach within their jurisdictions. Such awareness could stimulate discussions about policy and any necessary political action.


For the first two decades of existence for Beyond AIDS, two separate corporations were maintained: the main Beyond AIDS organization for political work and to maintain the organization, and the Beyond AIDS Foundation for education, research, and other charitable purposes (including our internship/fellowship program and educational Website content). The Foundation was registered with IRS as a 501(c)(3) tax-deductible, charitable corporation, while Beyond AIDS was registered as a tax-exempt but not tax-deductible 501(c)(4) corporation. For all lobbying work, Beyond AIDS funds were utilized.

At the Annual Meeting of Beyond AIDS in December 2018, the membership present voted to merge the two corporations, with the Foundation becoming the surviving corporation. To accomplish this, a number of documents including Articles of Incorporation of the Foundation are being revised during 2019. The plan is for the merger to become effective at the beginning of 2020.

A major reason that two corporations were formed in the first place was that originally, we anticipated that a substantial portion of of the income of Beyond AIDS would be needed for political work, which would not be legitimately deductible. That has not proven to be the case. Any work to promote legislation is expected to consume a non-substantial proportion of the income of the Foundation, which should not threaten the tax status of that surviving corporation. The merger will simplify paperwork, corporate expenses, banking, and bill paying.

Since the Trump-era tax legislation took effect in 2018, having a 501(c)(3) tax-deductible corporation has not been as important as in the past, because charitable contributions by individuals only become deductible when they exceed $24,000 in a year. However, maintaining such a corporation has other benefits, such as making us eligible to receive grants.

Under the new arrangement, the Beyond AIDS Foundation will have no members, and all authority will be in the hands of the Board of Directors. However, contributors will be known as "supporters," and will be eligible to serve on committees and to attend open Board meetings.

Anyone with questions is welcome to write to foundation@beyondaids.org.

Monday, January 15, 2018


The last two months of 2017 were busy ones for Beyond AIDS and its Foundation.

The Annual Meetings of Beyond AIDS and of the Foundation Board were  held on November 19 in Redlands, CA. The legislative efforts of Beyond AIDS were not particularly effective. A California bill supported by Beyond AIDS (AB  1534), to permit the same physician to serve alternately as a patient's primary care provider and his/her HIV consultant, almost passed, but was stalled at the last minute and will become a two-year bill. Another California bill (SB 239) strongly opposed by Beyond AIDS, to eliminate all penalties for knowingly exposing others to HIV or other communicable diseases, passed and was signed into law.

Officers and directors for the Beyond AIDS Board were elected to serve in 2018 and 2019. The Board in turn appointed the Foundation Board. Ron Hattis will continue as President of Beyond AIDS, and Gary Richwald will be the new President of the Foundation.

In a discussion of projects for 2018, interest was expressed in promoting simultaneous screening for HIV, other STDs, and viral hepatitis. With regard to legislation, Beyond AIDS will continue its efforts to coordinate with the AIDS Healthcare Foundation, and in California, with the California Medical Association and Health Officers Association.

World AIDS Day, as always, was December 1, and the Beyond AIDS Foundation co-sponsored a 4-hour continuing education program on HIV at Loma Linda University, covering a wide range of topics including legal testing requirements in California, early treatment to benefit both the patient and public health, management of clinical problems in HIV care, pre-exposure prophylaxis (PrEP), and questions presented to a panel of public health and HIV specialists. The slide presentations and videos are available to all on this Beyond AIDS Website.  The Foundation is planning to conduct a one-hour Webinar early in 2018, on early HIV treatment and proper use of PrEP. Work is continuing in an effort to publish the findings of a national survey of state and territorial HIV/AIDS directors. The internship/fellowship program also continues.
Panel discussion 12-1-17 at Loma Linda, L to R Drs. Daniel Pearch, Steven Larson, Ron Hattis, and Prashanth Bhat

By vote of the Beyond AIDS Foundation Board, the annual Nettie award for significant contribution to HIV prevention and control was given to Matthew Golden, health officer and HIV director for King County/Seattle Department of Public Health. He won the award for leading the first successful North American campaign to reach the UNAIDS goal of "90-90-90." This means that 90% of infected persons were diagnosed, 90% of them were started on anti-viral medication. and 90% of those reached undetectable viral loads. San Francisco is reportedly close behind in achieving the same.
The award for Dr. Matthew Golden

Saturday, December 16, 2017


In its biennial election on November 19, 2017, Beyond AIDS selected the following officers and directors to serve during 2018 and 2019:

President:  Ronald P. Hattis, MD, MPH (California)
Vice-Pres:  Jeffrey Klausner, MD, MPH (California)
Gary A. Richwald (California)
Treasurer:  Richel Strydom, MD, MPH (California)
Franklyn N. Judson, MD (Colorado)
                   Elizabeth Kidder, MD, MPH (Washington, DC)
                   I. Jean Davis-Hatcher, PhD, PA (California) (from 10/18)
                   Monica M. Sweeney, MD, MPH (New York)

Past-Pres.: Cary Savitch, MD (California)

The Advisory Council will consist of:

Denise Bleak, MSN, PHN (California)
Deanna Stover, PhD, FNP (California) (from 10/18)

Josileide Gaio, MPH (California)
Peter Kerndt, MD, MPH (California)
Marsha Martin, DSW (Washington, DC)
Cesar Reis, MD, fellow (California)                             

The subsidiary Beyond AIDS Foundation, a 501(c)3 charitable corporation, will be governed by the following Board (elected by the membership of Beyond AIDS):

President:   Gary Richwald, MD, MPH (California)
Vice-Pres.:  Monica M. Sweeney, MD, MPH (New York)

Secretary:   Ronald P. Hattis, MD, MPH (California)
Treasurer:   Richel Strydom, MD, MPH (California)
Franklyn N. Judson, MD, MPH (Colorado)
                     Elizabeth Kidder, MD, PhD, MPH (Washington, DC)

                     Jeffrey Klausner, MD, MPH (California)
  Cary Savitch, MD (California) 
   I. Jean Davis-Hatcher, PhD, PA (California) (from 10/18)                                                                                          
The Scientific Committee is assigned by Beyond AIDS  to work with the Foundation. Members, as of November 2017:

Franklyn N. Judson, MD, MPH (Colorado) and
Monica M. Sweeney, MD, MPH (New York), Co-Chairs
I. Jean Davis-Hatcher, PhD, PA, DC (California)
Ronald P. Hattis, MD, MPH (California)
Elizabeth Kidder, MD, PhD, MPH (Washington, DC)
Peter Kerndt, MD, MPH (Mozambique)
Jeffrey Klausner, MD, MPH (California)
Gary A. Richwald, MD, MPH (California)
Cary Savitch, MD (California)
Colin Shepherd, MD (China)
Deanna C. Stover, PhD, FNP (California)

The memberships of this and other committees are subject to change and available on request.



Ron Hattis is continuing as President of Beyond AIDS, and Secretary of our subsidiary tax-deductible Foundation.  When the organization was founded, he was the first Vice-President, and later but before his current offices served as Secretary, as well as President of the Foundation. He has been active in contacts with federal leaders, and in Beyond AIDS' legislative efforts in California, and has represented our organization in consultations with the California Office of AIDS. He developed the original Bylaws for both the membership organization and the foundation, and has mentored many of our past interns.  

He is a physician, board-certified in Public Health/Preventive Medicine, and lives in Redlands, California.  He was formerly the Chief of Medical Services at a large state hospital, where in addition to medical management, he was in charge of HIV testing and training HIV educators for 20 years, and he treated HIV/AIDS patients at the infectious disease clinic.  Since retiring from that position, he has worked part-time in clinical medicine, currently including student health and primary care. He has been an HIV clinician/specialist. 
Dr. Hattis is an Associate Professor of Preventive Medicine Loma Linda University School of Medicine, where he has lectured on HIV as a representative of our Foundation.  He spent 23 years with a disaster medical assistance team, serving at the World Trade Center, Hurricane Katrina, Hurricane Ike, and the Northridge earthquake.

Other past positions in reverse order have included teacher of family medicine, county health officer, country family physician (on Kauai in Hawaii), and Epidemic Intelligence Service Officer for the Centers for Disease Control and Prevention (assigned through field services to the Hawaii Department of Health).  

His goals for Beyond AIDS over the next two years include completing research and continuing to develop proposals for more effective implementation of the National HIV/AIDS Strategy; and continuing to be involved with legislation in California and important states, as well as at the federal level. In particular, he plans to continue to work to promote the HIV care continuum; to utilize HIV reporting to trigger outreach for referral of patients to treatment, partner services, and other services to prevent transmission; and to enhance HIV prevention science. 

Jeffrey D. Klausner is a UCLA Professor of Medicine and Public Health. He is a physician, board certified in Internal Medicine and Infectious Diseases. He served as a CDC Epidemic Intelligence Service Officer 1995-1997, Deputy Health Officer and Director of STD Prevention and Control Services, San Francisco Department of Public Health, 1998-2009, and Branch Chief for HIV and TB, CDC South Africa, 2009-2011. 

Dr. Klausner has been a leader in implementing the public health approach to HIV prevention and control through policy and programmatic activites resulting in the streamlining and evaluation of routine HIV testing, early HIV case detection with HIV RNA screening, linkage-to-care and contact tracing and partner notification services.  In addition Dr. Klausner through his epidemiologic research, identified the role that bacterial STDs, the Internet, sex clubs, methamphetamine and Viagra played in augmenting the risk of HIV tranmission and implemented successful population-based programs to mitigate those risk factors. In collaboration with community leaders and organizations, he inititated sexual health campaigns and peer-led sexual health services for sex workers and gay men in San Francisco which have been replicated globally. 

Dr. Klausner has been conducting research in laboratory-based diagnostics for HIV infection and other STDs since the early 1990s and is considered an expert in infectious disease detection and management. He has a busy clinical HIV/AIDS practice in Los Angeles and regularly attends on the infectious diseases consultation service at UCLA Ronald Reagan Hospital.  Dr. Klausner brings nearly two decades of public health, clinical and research experience to the Board, much of it specific to HIV prevention. 


Deanna Stover is the Chief Executive Officer of the Community Health Association Inland Southern Region. She began her nursing career in 1979 as a medic serving in the United States Air Force. She earned her MSN/FNP degree in 1997 and a PhD in Nursing, Health Policy from Loma Linda University in 2011. She has held leadership positions in both hospital and ambulatory / outpatient health care environments.

She has actively worked in the medical arena for over 30 years with training and expertise in community-based health care, health policy, HIV/AIDS health care, occupational medicine and nursing, and advance practice nursing as a family nurse practitioner and clinical nurse specialist. She holds a certificate as an Advanced HIV Nurse Clinician from USC Medical Center, AIDS education training center (1995) and has provided HIV/AIDS training for healthcare providers. She is an adjunct professor for the Department of Nursing at California State University, San Bernardino.

She has served on organizational Board of Directors at the state, local, and national  levels, including immediate past-president of the Beyond AIDS Foundation, and Secretary of Beyond AIDS


Gary Richwald received his engineering degree from Cornell University, medical degree from the Mount Sinai School of Medicine in New York City, and Master's in Public Health (MPH) in health services research/epidemiology from UCLA. He completed his specialty/subspecialty training in internal medicine, geriatrics, and preventive medicine at the University of Michigan and UCLA. He was a Robert Wood Johnson Foundation Scholar at UCLA/RAND in health policy services research.

From 1981 to 1989, Dr. Richwald was a full-time faculty member at UCLA in the Schools of Public Health/Medicine, and subsequently served as Director and Chief Physician, L.A. County Sexually Transmitted Disease Program (1989-2000). He has been a consultant on STD policy and clinical care for the AME, American Sexual Health Association (ASHA), and CDC. He chaired the California STD Control Association for 3 terms, and was a founding member, National Coalition of STD Directors. He has worked with GSK, Novartis, Abbott, Merck, 3M Pharmaceuticals, and Focus Technologies/Quest Diagnostics in the development of STD-related health care technology.  
STRYDOM, MD, MPH, Treasurer

Richel Strydom, MD, MPH, the current Beyond AIDS, Inc. and Beyond AIDS Foundation Treasurer,  is presently a third year Loma Linda University (Loma Linda, CA) Preventive Medicine Resident Physician.  Prior to beginning her current Preventive Medicine Residency Training, Richel obtained a Masters degree in Public Health, with a Global Health Concentration, at the Loma Linda University School of Public Health.  Prior to her MPH studies, Richel completed a couple of years of Family Medicine Residency Training, in Tallahassee, FL.

Dr. Strydom was born and raised in the country of South Africa.  The HIV burden of the South African population, as well as the HIV burden within many African and other countries, including within the U.S.A., have contributed to a strong, persistent public health problem.  In July 2016, shortly following the June 2016 launch of   the “Test and Treat” HIV care approach in Lesotho, the first country in sub-Saharan Africa to formally adopt this strategy recommended by UNAIDS in 2015, Richel had the privilege of attending a briefing on the new program while doing a rotation in HIV and Tuberculosis care and prevention, at Maluti Adventist Hospital, in Lesotho. 

While a Family Medicine Resident in training, in Tallahassee, FL, Richel worked as a volunteer to provide education and comprehensive support to people who are living with HIV, within an eight-county area of Florida. Earlier, while attending medical school at the American University of the Caribbean School of Medicine, she worked with students and faculty members to actively promote knowledge about, and the prevention of, HIV and STIs. Prior to that, while attending North Carolina State University, she worked with the Alliance of AIDS Services – Carolinas (AASC) as a volunteer “care partner” for a young woman living with HIV. 

Richel feels compelled to work to improve HIV care and prevention policies and practices. Serving with Beyond AIDS furthers that aim.

Frank Judson received his BA from Wesleyan University in 1964, his MD from the University of Pennsylvania in 1968, and his house staff training from the University of Wisconsin Hospitals (internal medicine) and the University of Colorado (infectious diseases).  He was an Epidemic Intelligence Service officer with the Centers for Disease Control assigned to the Colorado Department of Public Health  (1970-72), and Scientific Liaison, Global Program on AIDS, Geneva (1990 -91).  He is board-certified in internal medicine, infectious diseases and preventive medicine. 

For over 41 years, his research interests have concentrated on the epidemiology and control of sexually transmitted infections including hepatitis B and HIV.  His public health policy interests have run the gamut from childhood and adolescent vaccine programs, to urban air pollution, bioterrorism preparedness, and tobacco, tuberculosis, influenza, and HIV prevention and control.  He has authored or co-authored more than 270 scientific publications.  

Dr. Judson has served as President of the American STD Association (ASTDA), President of the International Society for STD Research (ISSTDR), President of the International Union Against the Sexually Transmitted Infections (IUSTI), Chairman of the Board of the American Social Health Association (ASHA), Chief of Infectious Diseases for the Denver Health Medical Center (1983-2002), and Director of the Denver Public Health Department (1986-2004). He has been a member of the Presidential Advisory Council on HIV/AIDS (PACHA), the CDC/HHS Advisory Committee on Immunization Practices (ACIP), the Board of Regents of the American College of Preventive Medicine, and the Colorado State Board of Health. Currently, he is a member of the Colorado Governor’s Expert Emergency Epidemic Response Committee (GEEERC) and Professor, Department of Medicine (Infectious Diseases) and the Colorado School of Public Health, University of Colorado, Denver. 

Elizabeth (Betsy) Kidder, MD, PhD, MPH received her Master's in Public Health, Medical Degree, and PhD in Public Policy and Health Policy from the George Washington University. She completed her residency in Internal Medicine and Primary Care program at the George Washington University Hospital.  Her career and research interests focus on access to quality health care by underserved communities, improving access to addiction treatment, and implementing innovative and patient-centered cancer screening options.  Her dissertation research investigated self-administered HPV testing as a cervical cancer screening option for underscreened women.

Betsy joined Beyond AIDS in 2001 as an intern, and has served as a Board member since 2003. She received her Master's in Public Health in 2004 and her Medical Degree in 2011, both from the George Washington University. She also completed a doctorate there in health policy.

As a public health professional, she has worked in Rome, Italy with the United Nations on the development team for the "Initiative to End Child Hunger" - a collaboration between the World Bank, the United Nations Children's Fund, and the World Food Program. Previous to that, she worked with the Global Health Council in Washington, DC on issues related to HIV/AIDS and child health, as a part of a national PBS media and outreach campaign in global health. She has also worked at the Department of Defense's HIV/AIDS Prevention Program as well as the Futures Group, where she assisted with the research and writing of a "What Works" program guide for developing country policymakers on evidence-based practices in HIV/AIDS/STI prevention. 

Her interest in issues related to HIV was initially sparked by the case of Nushawn Williams, a young man who knowingly spread HIV in her small hometown community and high school. After that incident, she traveled to South Africa, where she studied the epidemic in the Eastern Cape, taught an HIV/AIDS education class, and volunteered in a pediatric HIV clinic, all of which deepened her commitment to staying involved with HIV advocacy through her career.


Monica Sweeney is Vice Dean for Global Engagement and Chair, Dept. Health Policy and Management, School of Public Health, State University of New York (SUNY) Downstate Medical Center.  Additionally, she is the chair of the SUNY Downstate Medical Center's Association of Council Members and College Trustees.
Before that, she was the Assistant Commissioner of Health for New York City. Previously, for six years, she was in charge of the NYC Bureau of HIV/AIDS Prevention and Control. Her responsibilities there included oversight of programs and budgets for prevention; care and treatment (Ryan White); Housing Opportunities for People With AIDS (HOPWA); and the epidemiology/Field Services Unit. 

Previously, she was the medical director and vice president for medical affairs in a Federally Qualified Health Center in Bedford Stuyvesant, Brooklyn NY.  The community served was medically and economically deprived and HIV/AIDS was one of many challenges she addressed daily during her 17 years in Bedford Stuyvesant.  During her tenure there, in addition to direct patient care, she became involved in policy and advocacy and had the opportunity to work with Assemblywoman Nettie Mayersohn to get her historic legislation (the Baby AIDS Bill, and Named-based Reporting) passed -- over almost insurmountable opposition.

Dr. Sweeney is a board-certified internist and geriatrician with a masters degree in public health.  She has always combined individual and public health in her practice, by working with the Medical Society for the State of New York (MSSNY), the National Association of Community Health Centers (NACHC), and the American College of Physicians (ACP) and by serving on the President’s Advisory Council on HIV/AIDS (PACHA).  Prior to election to the position of Vice-President, she was a Director on the Beyond AIDS Board, and before that she served on the Advisory Council. Her goals as Vice-President include working diligently to broaden the reach of the only AIDS organization that has always used sound public health policy to fight the epidemic.

CARY SAVITCH, MD, Immediate Past-President

Cary Savitch was one of the Founding Members of Beyond AIDS, organized its founding meetings, and was elected its first President. He has served on the Board of Directors since the founding of the organization.  He recruited many of the early members of the organization by speaking to friends, colleagues, and patients about the need for HIV reform, writing a book about the subject, and giving talks on HIV, especially in Ventura County and the surrounding area where the founding meetings were held. 
He is an infectious disease physician, and has taken care of AIDS patients for the past 33 years (starting even before the disease had a name). 

In 1997, he published a book, “The Nutcracker is Already Dancing,” which highlighted the lack of application to HIV of sound public health practices that had been successfully utilized for diseases such as syphilis and tuberculosis. He believes strongly that the mission of Beyond AIDS, to stop the transmission of HIV, is the direction we must take in order to save lives in this epidemic.

He expresses pride in the time he has already spent with Beyond AIDS, which he believes is the only organization willing to stand up and support the necessary public health policies needed to contain HIV. His goals are to continue these efforts in every and any capacity needed, and to encourage others to join our battle for HIV/AIDS prevention.